AAPL 250.9362 1.1636% MSFT 439.85 0.5624% NVDA 132.26 2.5987% GOOGL 190.36 1.0403% GOOG 191.585 0.7547% AMZN 224.7026 1.8967% META 605.1 1.3245% AVGO 221.57 -0.9167% TSLA 434.8 -1.211% TSM 195.3 -0.133% LLY 758.87 -0.7637% V 315.9 1.9756% JPM 234.325 1.7168% UNH 493.79 -1.1867% NVO 103.7 -2.1329% WMT 93.89 0.3634% LVMUY 130.52 0.7721% XOM 105.67 -0.7048% LVMHF 649.5 0.6649% MA 526.755 1.3068%

India Globalization Capital Inc

Healthcare US IGC

0.375USD
0.01(4.17%)

Last update at 2024-12-19T18:52:00Z

Day Range

0.360.38
LowHigh

52 Week Range

0.250.49
LowHigh

Fundamentals

  • Previous Close 0.36
  • Market Cap18.87M
  • Volume147932
  • P/E Ratio-
  • Dividend Yield5.22%
  • EBITDA-10.31000M
  • Revenue TTM1.34M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM 0.44M
  • Diluted EPS TTM-0.2

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -11.50600M -15.01600M -8.81100M -7.31500M -4.09500M
Minority interest - - - - -
Net income -11.44100M -14.60400M -8.98000M -8.09700M -4.09700M
Selling general administrative 8.55M 13.29M 7.91M 5.97M 3.52M
Selling and marketing expenses - - - - -
Gross profit 0.44M 0.19M 0.11M 0.12M 0.13M
Reconciled depreciation 0.66M 0.65M 0.48M 0.14M 0.06M
Ebit -11.57100M -15.42800M -8.72400M -6.86400M -4.64300M
Ebitda -10.91400M -14.72800M -8.07700M -5.93800M -4.58400M
Depreciation and amortization 0.66M 0.70M 0.65M 0.93M 0.06M
Non operating income net other - - 0.08M 0.33M 0.55M
Operating income -11.57100M -15.42800M -8.72400M -6.86400M -4.64300M
Other operating expenses 12.48M 15.82M 9.62M 10.94M 9.76M
Interest expense -0.06500M -0.41200M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00200M
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.06500M -0.41200M 0.17M 0.78M 0.00200M
Total revenue 0.91M 0.40M 0.90M 4.07M 5.12M
Total operating expenses 12.01M 15.62M 8.84M 6.98M 4.78M
Cost of revenue 0.47M 0.20M 0.79M 3.96M 4.98M
Total other income expense net 0.07M 0.41M -0.08700M -0.45100M 0.55M
Discontinued operations - - - - -
Net income from continuing ops -11.50600M -15.01600M -8.81100M -7.31500M -4.09700M
Net income applicable to common shares -11.50600M -15.01600M -8.81100M -7.31500M -4.09700M
Preferred stock and other adjustments - - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Total assets 17.18M 26.83M 35.87M 28.98M 34.47M
Intangible assets 1.17M 0.92M 0.41M 0.25M 0.18M
Earning assets - - - - -
Other current assets 0.36M 0.51M 0.20M 1.04M 0.02M
Total liab 2.27M 2.94M 3.06M 2.45M 0.89M
Total stockholder equity 14.91M 23.89M 32.80M 26.54M 33.57M
Deferred long term liab - - - - -
Other current liab 0.36M 1.46M 0.43M 0.30M 0.04M
Common stock 118.97M 116.02M 109.72M 94.75M 94.04M
Capital stock 118.97M 116.02M 109.72M 94.75M 94.04M
Retained earnings -100.66500M -89.15900M -74.14300M -65.36700M -58.05200M
Other liab 0.02M 0.02M 0.01M 0.02M 0.01M
Good will - - - 0.25M 0.18M
Other assets 1.00M -0.00100M 0.60M 0.61M 0.88M
Cash 3.20M 10.46M 14.55M 7.26M 25.61M
Cash and equivalents 3.20M 10.46M 14.55M 7.26M 25.61M
Total current liabilities 1.90M 2.44M 2.37M 1.95M 0.88M
Current deferred revenue 0.88M - 1.16M 0.84M 0.47M
Net debt -2.71500M -9.97200M -13.56300M -6.72300M -25.56000M
Short term debt 0.13M 0.00300M 0.30M 0.05M 0.05M
Short long term debt - 0.00300M 0.30M 0.05M 0.05M
Short long term debt total 0.48M 0.49M 0.98M 0.54M 0.05M
Other stockholder equity -3.38900M -2.96800M -2.77400M 0.15M -2.41900M
Property plant equipment 8.54M 9.87M 11.33M 9.78M 5.89M
Total current assets 6.47M 15.11M 23.52M 17.76M 26.72M
Long term investments - 0.00000M 0.01M 0.01M 0.79M
Net tangible assets 13.74M 22.98M 32.40M 26.29M 33.39M
Short term investments 0.15M 0.00000M 0.08M 5.08M 0.78M
Net receivables 0.13M 0.60M 1.92M 0.13M 0.08M
Long term debt 0.14M 0.14M 0.28M - 0.00000M
Inventory 2.65M 3.55M 5.48M 4.25M 0.25M
Accounts payable 0.53M 0.98M 0.48M 0.76M 0.32M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -3.38900M -2.96800M -2.77400M -2.85000M -2.41900M
Additional paid in capital - - - - -
Common stock total equity - - 109.72M 94.75M 94.04M
Preferred stock total equity - - - - -
Retained earnings total equity - - -74.14300M -65.36700M -58.05200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.00M 0.94M 0.60M 0.61M 0.88M
Deferred long term asset charges - - - - -
Non current assets total 10.71M 11.72M 12.35M 11.23M 7.74M
Capital lease obligations 0.34M 0.34M 0.41M 0.48M -
Long term debt total 0.14M 0.14M 0.28M 0.00000M 0.00000M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -0.23500M -0.74200M 4.93M -9.54700M -0.20000M
Change to liabilities -0.45100M 0.50M -0.28700M 1.55M 0.28M
Total cashflows from investing activities -0.23500M -0.74200M 3.39M -9.54700M -0.26000M
Net borrowings -0.00300M -0.00300M 0.53M 0.53M -1.87800M
Total cash from financing activities 0.10M 4.14M 14.69M -0.05900M 27.60M
Change to operating activities 0.34M 0.05M -1.73200M 0.55M -0.30300M
Net income -11.50600M -15.01600M -8.81100M -7.31500M -4.09700M
Change in cash -7.26400M -4.08800M 7.29M -18.35200M 23.95M
Begin period cash flow 10.46M 14.55M 7.26M 25.61M 1.66M
End period cash flow 3.20M 10.46M 14.55M 7.26M 25.61M
Total cash from operating activities -7.04700M -7.46200M -10.80000M -8.67700M -3.33000M
Issuance of capital stock 0.10M 4.14M 14.16M 0.00000M 29.46M
Depreciation 0.66M 0.65M 0.48M 0.14M 0.06M
Other cashflows from investing activities 0.38M 0.00000M 4.98M -5.15800M -0.04500M
Dividends paid - - - - -
Change to inventory 0.90M 1.93M -1.23300M -3.99800M 0.24M
Change to account receivables 0.00500M 0.05M -0.04200M -0.04900M 0.47M
Sale purchase of stock 0.10M 4.14M 14.74M -0.05900M 29.48M
Other cashflows from financing activities -0.23500M -0.00300M 0.58M 0.06M 0.02M
Change to netincome 3.01M 4.37M 0.81M 1.55M 0.31M
Capital expenditures 0.62M 0.74M 1.59M 4.47M 0.06M
Change receivables - - -0.04200M -0.04900M 0.47M
Cash flows other operating - - -2.10500M -0.56600M -0.61500M
Exchange rate changes - - 0.01M -0.06900M -0.05600M
Cash and cash equivalents changes - - 7.29M -18.35200M 23.95M
Change in working capital 0.79M 2.54M -3.29400M -3.05800M 0.38M
Stock based compensation 2.84M 2.20M 0.66M 0.77M 0.61M
Other non cash items 0.62M 2.17M 0.17M 0.78M -0.28200M
Free cash flow -7.66600M -8.20400M -12.39200M -13.14300M -3.39000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IGC
India Globalization Capital Inc
0.01 4.17% 0.38 - - 14.05 1.40 12.71 -1.6614
NVO
Novo Nordisk A/S
-2.26 2.13% 103.70 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
-1.68 1.57% 105.12 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-55.6951 12.45% 391.80 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc
-4.445 0.62% 710.17 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

Profile

IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

India Globalization Capital Inc

10224 Falls Road, Potomac, MD, United States, 20854

Key Executives

Name Title Year Born
Mr. Ram Mukunda Pres, CEO & Director 1959
Ms. Claudia Grimaldi VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director 1971
Mr. Rohit Goel Sr. Director of Accounting & Principal Accounting Officer 1994
Mrs. Parveen Mukunda Corp. Sec. NA
Dr. Ranga C. Krishna M.D. Sr. Advisor 1964

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.